Document is current
Any future updates will be listed below
-
Authors
,
Rentsch, Christopher T. https://orcid.org/0000-0002-1408-7907
Edelman, E. Jennifer
Justice, Amy C.
Marshall, Brandon D. L.
Xu, Ke
Smith, Andrew H.
Crystal, Stephen
Gaither, Julie R.
Gordon, Adam J.
Smith, Rachel V.
Kember, Rachel L.
Polimanti, Renato
Gelernter, Joel
Fiellin, David A.
Tate, Janet P.
Kranzler, Henry R.
Becker, William C.
-
Funding
Funding for this research was provided by:
National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U10-AA013566)
National Institute on Drug Abuse (R01-DA040471, R01-DA12690)
U.S. Department of Veterans Affairs (i01-BX003341)
Yale School of Medicine Drug Use, Addiction, and HIV Research Scholars Program (K12-DA033312)
Agency for Healthcar Research and Quality (U19-HS021112, R18-HS023258)
- License Information
-
More Information
Article History
First Online: 17 July 2019
Compliance with Ethical Standards
:
: Dr. Kranzler is a Member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, and XenoPort. Drs. Kranzler, Gelernter, and A. Smith are also named as Inventors on PCT Patent Application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. The remaining authors have no conflicts of interest.
